The future of immunotherapy for diffuse large B‐cell lymphoma
J Duell, J Westin - International journal of cancer, 2025 - Wiley Online Library
With the introduction of anti‐CD19 chimeric antigen receptor (CAR) T‐cell (CAR T)
therapies, bispecific CD3/CD20 antibodies and anti‐CD19 antibodies, immunotherapy …
therapies, bispecific CD3/CD20 antibodies and anti‐CD19 antibodies, immunotherapy …
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
T Lu, J Zhang, ZY Xu-Monette, KH Young - Experimental Hematology & …, 2023 - Springer
Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line
immunochemotherapy, whereas nearly 30–40% of patients experience refractory or relapse …
immunochemotherapy, whereas nearly 30–40% of patients experience refractory or relapse …
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
Background Outcomes are poor for patients with large B-cell lymphoma who relapse after
CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR19). CD22 is a nearly …
CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR19). CD22 is a nearly …
Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
The efficacy of loncastuximab tesirine (lonca) following chimeric antigen receptor T-cell
therapy (CAR-T) progression/failure is unknown. Hence, we sought to examine real-world …
therapy (CAR-T) progression/failure is unknown. Hence, we sought to examine real-world …
[HTML][HTML] Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy
Despite the success of CD19-targeted chimeric antigen receptor (CAR T)-cell therapy in
patients with relapsed/refractory large B-cell lymphoma (LBCL), there is a need for effective …
patients with relapsed/refractory large B-cell lymphoma (LBCL), there is a need for effective …
Relapsed or refractory large B‐cell lymphoma after chimeric antigen receptor T‐cell therapy: Current challenges and therapeutic options
R Del Toro‐Mijares, O Oluwole… - British Journal of …, 2023 - Wiley Online Library
Chimeric antigen receptor (CAR) T‐cell (CAR‐T) therapy can provide durable remission in
patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL) after failure of …
patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL) after failure of …
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy
R Karmali, R Machhi, N Epperla, G Shouse… - Blood …, 2024 - ashpublications.org
Chimeric antigen receptor (CAR) T-cell (CAR-T) immunotherapy is an effective therapy for
relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). However, data are limited on …
relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). However, data are limited on …
[PDF][PDF] Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas
JD Bender, S Damodharan, CM Capitini… - Blood …, 2024 - ashpublications.org
COI notes: CC: Honoraria for advisory board membership for Bayer, Elephas, Nektar
Therapeutics, Novartis, and WiCell Research Institute TCQ: No relevant disclosures …
Therapeutics, Novartis, and WiCell Research Institute TCQ: No relevant disclosures …
How I treat refractory/relapsed diffuse large B‐cell lymphomas with CD19‐directed chimeric antigen receptor T cells
A Nagler, VM Perriello, L Falini… - British Journal of …, 2023 - Wiley Online Library
Chimeric antigen receptor (CAR) T cells targeting CD19 represent a promising salvage
immunotherapy for relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL) …
immunotherapy for relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL) …
CAR T-cell therapy in aggressive lymphomas—identifying prognostic and predictive markers
A Mussetti, N Fabbri, A Sureda - Hematology, 2023 - ashpublications.org
We discuss different pre-infusion, post-infusion and post-CAR T-cell relapse prognostic
factors influencing the outcomes of anti-CD19 CAR T-cell therapy in patients with relapsed …
factors influencing the outcomes of anti-CD19 CAR T-cell therapy in patients with relapsed …